# Tomonari Abe, President of Abe Yoando Pharma, Selected as First Japanese Speaker at Longevity Investors Conference 2026 in Switzerland

- Link: https://www.thailand-business-news.com/pr-news/tomonari-abe-president-of-abe-yoando-pharma-selected-as-first-japanese-speaker-at-longevity-investors-conference-2026-in-switzerland
- Published: 2026-09-14T13:00:00+07:00
- Author: PR Newswire

– Head of 295-year-old Japanese Pharmaceutical Pioneer to Present Asia’s Longevity
Growth Strategies and Bioscientific Research Initiatives at Prestigious Conference–

TOKYO and GSTAAD, Switzerland, Sept. 14, 2026 /PRNewswire/ — Abe Yoando Pharma Co.,
Ltd., a nearly 300-year-old pharmaceutical company headquartered in Tokyo and advancing
longevity science, announced that its President Tomonari Abe has been selected as
the first Japanese speaker (*1) to present at the Longevity Investors Conference
2026, to be held in Gstaad, Switzerland, from September 14 to 17, 2026.

Image: [https://drive.google.com/file/d/1loBgPPyXeUUfvwbmmjQUIyxxQJ927XEB/view?usp=sharing](https://drive.google.com/file/d/1loBgPPyXeUUfvwbmmjQUIyxxQJ927XEB/view?usp=sharing)

As global interest in healthy longevity expands, the market is projected to reach
approximately $8 trillion by 2030 (*2). Japan, facing an aging population ahead 
of other nations, is increasingly recognized by international investors and researchers
as a pivotal region for longevity research and market validation. Awarded as one
of the 20 finalist teams in the global XPRIZE Healthspan competition, Abe Yoando
Pharma integrates centuries-old wellness traditions with modern biotechnology to
advance scientific longevity initiatives.

At the conference, Abe will present on the theme: "The Longevity Opportunity in 
Asia: Building the Infrastructure for an Aging World."

"It is an honor to present Japan’s potential to leading global investors," said 
Abe. "Japan’s demographic landscape provides unique insights for longevity research.
By combining nearly three centuries of traditional expertise with cutting-edge bioscience,
we aim to demonstrate scalable, global growth strategies originating from Asia."

Abe Yoando Pharma remains focused on advancing research and development of high-
purity nicotinamide mononucleotide (NMN) and conducting joint scientific studies
with academic research institutions. Through international collaboration, the company
aims to support global healthy aging initiatives through rigorous scientific inquiry
into cellular mechanisms, including sirtuin genes.

About Abe Yoando Pharma Co., Ltd.
Founded in 1731 as official physicians to the 
shogun of the Matsudaira clan, Abe Yoando Pharma has evolved over nearly 300 years
to advance health and longevity science. Combining heritage with modern biotechnology,
the company pioneers NMN research and longevity science. Abe Yoando Pharma is among
the 20 finalist teams selected out of 799 entries across 58 countries in the XPRIZE
Healthspan competition.

Official website: [https://corp.abeyoando.co.jp/?lang=en](https://corp.abeyoando.co.jp/?lang=en)

Notes & Reference Links
(*1) First Japanese speaker: Based on Abe Yoando Pharma’s
internal research as of September 2026, referencing the official speaker directory
published by the Longevity Investors Conference since its inauguration.

(*2) Longevity market projection: Source: UBS Chief Investment Office (CIO) Research
Report, "Investing in Longevity," published by UBS Group AG / UBS SuMi TRUST Wealth
Management.

Reference URL: [https://www.ubs-sumitrust.com/cio-research/report/6474](https://www.ubs-sumitrust.com/cio-research/report/6474)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Tomonari Abe, President of Abe Yoando Pharma, Selected as First Japanese Speaker at Longevity Investors Conference 2026 in Switzerland ](http://www.prnasia.com/story/archive/5046645_HK46645_0?rand=184833)